Novo Nordisk A/s Stock News

Citigroup lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a neutral rating in a report published on Monday morning, The Fly reports. Several other research firms have also issued reports on NVO. Bryan, Garnier & Co lowered Novo Nordisk A/S from a buy rating to a sell rating and set a []

Dynamic Advisor Solutions LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,386 shares of the companys stock, valued at approximately $229,000. Other hedge funds have also recently added to or reduced their stakes []

Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at Danske from a buy rating to a hold rating in a report issued on Monday, The Fly reports. Several other brokerages also recently commented on NVO. Citigroup restated a buy rating on shares of Novo Nordisk A/S in a research report on Monday, August 23rd. [] The post Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Hold at Danske appeared first on ETF Daily News .

Novo Nordisk shares slump on U.S. supply challenges for obesity drug

Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a report issued on Friday, Analyst Price Targets reports. NVO has been the subject of several other research reports. SEB Equities upgraded Novo Nordisk A/S from a hold rating to a buy rating in a research [] The post Deutsche Bank Aktiengesellschaft Lowers Novo Nordisk A/S (NYSE:NVO) to Hold appeared first on ETF Daily News .

Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States

(PLX AI) - Novo Nordisk shares may drop more than 5% in Copenhagen after another delay in normalizing supply for its Wegovy obesity drug, analysts at Carnegie said. Novo Nordisk said it does not e

Lumature Wealth Partners LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 14.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,768 shares of the companys stock after selling 299 shares during the quarter. Lumature Wealth Partners LLCs holdings in Novo Nordisk []

Benedict Financial Advisors Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.3% in the third quarter, Holdings Channel reports. The institutional investor owned 26,276 shares of the companys stock after selling 342 shares during the period. Benedict Financial Advisors Inc.s holdings in Novo Nordisk A/S were worth $2,523,000 as of its []

The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Steve Grasso, Jeff Mills and Nadine Terman.

Carderock Capital Management Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,250 shares of the companys stock, valued at approximately $120,000. Other institutional investors have also []

Bagsværd, Denmark, 17 December 2021 - Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy pens for the US market has temporarily stopped deliveries and manufacturi

Bagsværd , De n mark, 17 December 2021 Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy ® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices.

Novo Nordisk A/S with ticker code (NVO) have now 2 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 118.23 and 114.45 calculating the average target price we see 116.34. With the stocks previous close at 116.46 this is indicating there is a potential downside of -.1%. The 50 day MA is 109.09 while the 200 day moving average is 91.2. The company has a market capitalisation of $266,893m. Visit the company website at: https://www.novonordisk.com [stock_market_widget type="chart" symbol="NVO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.